additives | Clarifi ers & nucleators


Figure 2A (left) shows development of haze as a function of gamma irradiation dose. There is no substantial difference in the haze values (experimental error of +/- 5%). Figure 2B (right) shows that the low haze values are roughly maintained after oven aging at 60˚C for 21 days Source: BASF


chemistries illustrates that we can “do more with less,” since XT 386 is at less than 10% of traditional sorbitol concentrations. Additional important ancillary benefi ts include signifi cantly reduced plate-out and better organoleptics due to the much lower loadings of our high performance clarifi er technology.”


Below: Clariant used its Mevopur nucleation technology to overcome pigment-relat- ed shrinkage issues for a producer of auto-injectors


Colour control Staying in the medical sector, speciality chemicals company Clariant explains how its Mevopur additives, including nucleators, can help the makers of disposable drug-delivery devices enhance product marketability and increase patient adherence to treatment. “The way in which pharmaceuticals are packaged and used by patients is changing rapidly and colour has an impor- tant role to play,” says Steve Duckworth, Clariant’s Global Head, Healthcare Polymer Solutions. “Not only does colour help identify products, it also can make delivery devices more attractive and thus may help to increase the likelihood that patients will adhere to their treatment regimen.” However, colour also can introduce processing vari- ability. As noted earlier, pigments have an infl uence on how polypropylene and


other crystalline polymers shrink as they cool. This phenomenon may only become apparent during storage stability testing, or when an existing device is converted to a different colour. Colour-induced variations in caps and closures can also result in changes in ovality or leakage. In a case study cited by Clariant, a leading producer of


auto-injector devices wanted to market the same device in a range of colours but had encountered assembly problems due to variations in dimensions. Clariant was able to measure how different pigments infl uenced crystallization of the PP polymer chosen for the outer body. It proposed combining Mevopur colours with a Mevopur nucleating additive, which would eliminate the difference in crystallization and yield components with consistent dimensions regardless of colour. The optimized formula was developed into both a ‘ready- to- use’ Mevopur compound and a ‘combibatch’ concentrate to fi t with the customer’s different processing needs. Mevopur products use ingredients that have been


biologically evaluated to ISO10993 and USP <87> and <88> Class VI. “The fact that the nucleating additive is available as a Mevopur product gives the customer a level of regulatory support and change control that is not normally available but increasingly essential for materials used in many medical devices and pharma- ceutical packaging products,” says Duckworth.


Click on the links for more information:  www.millikenchemical.com  www.mayzo.com  www.kalama.emeraldmaterials.com  www.nj-chem.co.jp  www.basf.com  www.clariant.com


70 COMPOUNDING WORLD | May 2016 www.compoundingworld.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94